What the research found
NAD+ precursor compounds differ fundamentally in how they enter cells and affect blood versus tissue levels. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are single-molecule variants—NMN carries an extra phosphate group—that the body converts into NAD+. When taken orally, NR produces a larger spike in circulating blood NAD+ (approximately 2.7-fold increase from a 1,000 mg dose), whereas NMN shows more modest blood elevation but may deliver better performance gains in athletic contexts. The source indicates that NMN at 600–900 mg daily correlates with performance improvements in walking distance and oxygen utilization in muscle, while NR achieves higher absolute NAD+ levels in some tissues but not necessarily where athletes benefit most.
The mechanistic difference stems from how each molecule crosses cell membranes. NMN uses a specific transporter (Slc12a8), while NR must first convert to NMN intracellularly before raising NAD+ levels. Direct NAD+ supplementation itself is ineffective because the molecule is too large and charged to cross cell membranes naturally.
Why it matters for you
If you're supplementing NAD+ precursors to support recovery, mitochondrial function, or endurance performance, the choice between NR and NMN involves a practical trade-off. NR produces larger increases in bloodwork biomarkers you might track—blood NAD+ levels rise more dramatically—but NMN appears to deliver more consistent athletic performance benefits at moderate doses (around 600–900 mg split across the day). This suggests NMN may be better suited if your goal is measurable gains in work capacity or recovery between training sessions, even if your blood NAD+ numbers don't climb as sharply.
Cost matters here: both precursors run $40–100 monthly, placing them well within reach compared to IV NAD+ therapy (which costs substantially more annually and carries adverse effects for most users). Timing also influences outcomes—the source indicates afternoon dosing of NMN produces statistically significant performance improvements, suggesting split dosing strategies may optimize results better than single morning doses.
Caveats
- Most data compares compounds in limited human trials or animal models; long-term athletic outcome data in strength athletes specifically is sparse
- Blood NAD+ elevation doesn't necessarily predict muscle tissue NAD+ or functional benefit—tissue-specific responses vary
- Gut microbiome composition and individual transporter expression likely create wide person-to-person variability not captured in aggregate results
- The source conflates different outcome measures (blood biomarkers vs. performance tests vs. cellular NAD+ in isolated tissues) without clearly separating which comparison applies where
- No data presented on whether performance gains persist beyond the trial period or cumulate with months of use